Cotrimoxazole for Pneumonia
Introduction to Cotrimoxazole Use
- The American Gastroenterological Association recommends cotrimoxazole as the definitive first-line treatment for Pneumocystis jirovecii pneumonia (PJP) in immunocompromised patients, including HIV-infected patients with CD4+ counts <200/mL, transplant recipients, patients on triple immunomodulators, and patients with inflammatory bowel disease on intensive immunosuppression 1, 2, 3
Clinical Context
- The American College of Gastroenterology suggests that cotrimoxazole is not the first-line treatment for typical community-acquired pneumonia in children or adults, but it may be considered as second-line in resource-limited settings when amoxicillin fails, with higher failure rates compared to amoxicillin 4, 7, 8
- The Infectious Diseases Society of America recommends that for non-severe bacterial pneumonia in HIV-positive patients, amoxicillin should be used as first-line, regardless of cotrimoxazole prophylaxis status, and cotrimoxazole has added benefit of lowering mortality and infection rates in HIV populations when used for bacterial infections 5, 6, 7, 9
Special Populations
- The American Academy of Dermatology advises avoiding cotrimoxazole as first-line treatment for community-acquired pneumonia in malaria-endemic regions because it lacks anti-malarial activity, and instead recommends using amoxicillin for pneumonia and prescribing separate anti-malarial therapy if malaria cannot be excluded 7
- The Society for Healthcare Epidemiology of America suggests that if cotrimoxazole fails and referral is impossible, switching to injectable antibiotics (ceftriaxone, penicillin/gentamicin, or chloramphenicol) for broader coverage may be necessary 6, 7
Prophylaxis vs Treatment
- The European Crohn’s and Colitis Organisation recommends cotrimoxazole prophylaxis for patients on triple immunomodulators, HIV patients with CD4+ <200/mL, and liver transplant recipients for 6-12 months post-transplant 1, 2, 3